Regional tuberculosis (TB) centres of the Yangon and Mandalay Regions of Myanmar, which account for 65% of all notified rifampicin-resistant tuberculosis (RR-TB) cases countrywide.
Objective is to determine 1) initial loss to follow-up (LTFU), 2) treatment delay, and 3) factors associated with initial LTFU and treatment delay among RR-TB patients residing in the Yangon and Mandalay regions diagnosed using Xpertw during January–August 2016.
This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)
Htet KKK, Soe KT, Kumar AM V, Saw S, Maung HMW, Myint Z, Khine TMM. Rifampicin-resistant tuberculosis patients in Myanmar in 2016 : how many are lost on the path to treatment ? International Journal of Tuberculosis & Lung Diseases. 2018;22(4):385–92.
Rifampicin-resistant tuberculosis patients in Myanmar in 2016: how many are lost on the path to treatment?